Skip to main content
TipRanks
Go Ultimate75% OFF

Cellectis SA (ALCLS) AI Stock Analysis

4 Followers
FR:ALCLS

Cellectis SA

(Paris:ALCLS)

Select Model
Rating:42Neutral
Price Target:EUR 1.00â–¼(-5.30% Downside)
Action:reiterated
Date:11/14/26

The score is primarily constrained by severe financial weakness, including recurring losses, balance-sheet erosion, and high cash burn. Weak technical positioning and the negative P/E provide little support, while the promising gene-editing pipeline and extended cash runway offer meaningful but highly speculative upside.

Positive Factors
HEAL-101 preclinical efficacyHEAL-101 has shown substantial target engagement and triglyceride reduction in multiple preclinical models, while management reported reassuring safety findings. If these effects translate clinically, the program could support a differentiated, durable therapy in severe hypertriglyceridemia.
Negative Factors
Sharp revenue contractionThe steep revenue decline highlights the volatility of Cellectis’s collaboration-led business model and its exposure to partner activity levels. Lower current revenue reduces internal funding capacity and makes future financial performance more dependent on new milestones or renewed collaboration spending.

Cellectis SA (ALCLS) vs. iShares MSCI France ETF (EWQ)

-80%-60%-40%-20%0%20%40%FR:ALCLS-70.46%EWQ+2.16%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 250.97M
Dividend Yield
―
Average Volume (3M)
455.25K
Price to Earnings (P/E)
-1.8
Beta (1Y)
0.66
Revenue Growth
-5.98%
EPS Growth
-8.67%
Country
France
Employees
227
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Cellectis SA Business Overview & Revenue Model

Company Description

Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric...

How the Company Makes Money

Cellectis makes money primarily through (1) collaboration and license-related revenue and (2) to a lesser extent, service/other operating revenue, with limited or no recurring product sales typical of many clinical-stage biotech companies. 1) Collabo...

Cellectis SA Earnings Call Summary

Earnings Call Date:Nov 13, 2026(Q3-2026)|% Change Since:-17.50%|Next Earnings Date:Mar 04, 2027
Earnings Call SentimentPositive

The call was strategically optimistic, centered on the transition to in vivo gene editing and encouraging preclinical results for HEAL-101 and HEAL-201. The company reiterated clinical timelines, described its LNP safety and prior clinical experience favorably, and expects cash runway into the second half of 2028. These positives were offset by the discontinuation of legacy cell therapy programs, planned headcount reductions, a substantial decline in revenue, lower cash and financial assets, and restructuring-related expenses. Overall, the number and strength of the stated pipeline and financing highlights outweighed the challenges.

Positive Updates

Strategic Transformation Toward In Vivo Gene Editing
Cellectis has transformed into an in vivo gene editing company focused initially on severe dyslipidemias, with HEAL-101 and HEAL-201 designed as single-injection therapies with the potential for long-lasting effects.

Negative Updates

Legacy Cell Therapy Programs Discontinued
Cellectis stopped development of the lasme-cel and eti-cel clinical programs. Enrollment has stopped, site closeout activities are underway, and treated patients will continue to be monitored under protocol-specified follow-up requirements.

Company Guidance

Cellectis said the investigator-initiated trial for HEAL-101 in China is on track, with preliminary clinical data expected in the second half of 2027; dose escalation is expected to start in Q1, the starting dose is anticipated to be effective, and by the end of year the company expects to start seeing the nine-month type of durability of effect. HEAL-201 is planned to enter phase I, with preliminary clinical data expected in the first half of 2028, while LDL-C reduction data will be provided in June. The company currently expects global headcount to be reduced by up to 70% from its pre-transition level over the course of 2026 and 2027, and expects to have a cash runway into the second half of 2028. Management expects HEAL-101 efficacy to be at least as good as the current treatments, is targeting the number of patients hitting under that target of 500, and estimates the target population at about 1.1 million across U.S. and EU5, or EU4 plus U.K.

Cellectis SA Financial Statement Overview

Summary

Financial performance is severely weak: persistent operating losses, declining equity, elevated leverage, and substantial negative operating and free cash flow outweigh the company’s high gross margins.

Income Statement

38Negative

Balance Sheet

32Negative

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue56.58M75.92M41.51M755.00K19.17M73.95M
Gross Profit42.25M55.04M41.51M18.00K17.40M37.67M
EBITDA-43.63M-21.12M-9.46M-92.64M-76.38M-78.42M
Net Income-65.27M-70.35M-36.76M-101.06M-98.69M-86.28M
Balance Sheet
Total Assets267.37M324.72M383.54M334.27M261.22M382.08M
Cash, Cash Equivalents and Short-Term Investments166.85M208.66M260.31M203.81M97.70M186.13M
Total Debt84.57M90.73M91.46M85.06M82.85M102.24M
Total Liabilities226.30M248.85M252.51M249.57M135.28M145.60M
Stockholders Equity41.07M75.91M131.03M84.69M117.97M221.29M
Cash Flow
Free Cash Flow-43.86M-44.10M19.15M-25.82M-89.89M-124.31M
Operating Cash Flow-41.69M-41.64M22.99M-24.75M-87.44M-104.56M
Investing Cash Flow33.13M-30.69M-102.81M-15.51M-2.76M7.28M
Financing Cash Flow-16.31M-16.81M89.11M82.86M1.15M47.52M

Cellectis SA Technical Analysis

Technical Analysis SentimentNegative
Last Price1.06

Price Trends

50DMA1.31Negative
100DMA1.98Negative
200DMA2.56Negative

Market Momentum

MACD-0.04Negative
RSI45.06Neutral
STOCH67.38Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALCLS, the sentiment is Negative. The current price of 1.06 is above the 20-day moving average (MA) of 1.04, below the 50-day MA of 1.31, and below the 200-day MA of 2.56, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 45.06 is Neutral, neither overbought nor oversold. The STOCH value of 67.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALCLS.

Cellectis SA Risk Analysis

Cellectis SA disclosed 102 risk factors in its most recent earnings report. Cellectis SA reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Cellectis SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

FR:ALCLS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FR:IPHFR:IPH48NeutralEUR 134.04M-2.35152.56%―-29.48%7.91%
FR:TNGFR:TNG48NeutralEUR 200.64M-4.31-29.36%―189.81%38.50%
FR:NANOFR:NANO47NeutralEUR 1.42B-25.3689.71%―――
FR:ALCLSFR:ALCLS42NeutralEUR 76.38M-1.78-94.14%―-5.98%-8.67%
FR:MAATFR:MAAT38UnderperformEUR 19.38M-0.54――-19.02%10.39%
FR:OSEFR:OSE38UnderperformEUR 40.77M-1.02-96.73%―-96.25%-197.89%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%FR:ALCLSFR:IPHFR:NANOFR:TNGFR:OSEFR:MAATDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
FR:ALCLS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
FR:ALCLSCellectis SA1.06-2.64-71.42%
FR:IPHInnate Pharma S.A.1.20-0.37-23.37%
FR:NANONanobiotix SA27.908.3442.64%
FR:TNGTransgene SA0.72-0.58-44.75%
FR:OSEOSE Immunotherapeutics1.73-3.97-69.60%
FR:MAATMaaT Pharma1.03-3.46-77.10%

Cellectis SA Corporate Events

Cellectis Showcases Promising One-Time Gene Editing Approach for Severe Hypertriglyceridemia

Oct 27, 2026

Cellectis has unveiled expanded preclinical data for .HEAL-101, an in vivo TALE base editing candidate targeting APOC3 for severe hypertriglyceridemia, at the European Society of Gene and Cell Therapy congress in Hamburg. The therapy uses liver-direc...

Cellectis Updates Share Capital and Voting Rights as of September 30, 2026

Oct 6, 2026

Cellectis reported that as of September 30, 2026, its share capital comprised 100,732,781 shares, corresponding to 105,563,044 voting rights, confirming its current capital and governance structure to the market. The updated share and voting rights d...

Cellectis pivots to in vivo gene editing and exits key CAR-T programs

Sep 14, 2026

Cellectis has approved a strategic shift to focus on in vivo gene editing, advancing two lead programs, .HEAL-101 and .HEAL-201, targeting severe hypertriglyceridemia and hypercholesterolemia with first Phase 1 data expected in China in 2027 and 2028...

Cellectis Plans September 14 Business Update Webcast for Global Investors

Sep 11, 2026

Cellectis SA will host an English- and French-language conference call and webcast on September 14, 2026 to provide a business update to investors and other stakeholders. The company plans to make a replay available on its website, underscoring its e...

Cellectis Updates Share Capital and Voting Rights as of August 31, 2026

Sep 3, 2026

Cellectis SA reported that as of August 31, 2026, its share capital consisted of 100,718,974 shares, corresponding to 105,568,956 voting rights. The update on capital and voting rights provides investors and market participants with greater transpare...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026